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Purpose: The objective of this study was to evaluate the optimal number of sampling sites for 
detection of methicillin-resistant Staphylococcus aureus (MRSA) colonization.
Methods: We performed a Medline search from January 1966 to February 2014 for articles 
that reported the prevalence of MRSA at different body sites. Studies were characterized by 
study design, country and period of the study, number of patients and/or isolates of MRSA, 
specimen type, sites of MRSA isolation, study population sampled, diagnostic testing method, 
and percentage of the MRSA isolates at each site in relation to the total number of sites.
Results: We reviewed 3,211 abstracts and 177 manuscripts, of which 17 met the criteria for 
analysis (n=52,642 patients). MRSA colonization prevalence varied from 8% to 99% at different 
body sites. The nasal cavity as a single site had MRSA detection sensitivity of 68% (34%–91%).
The throat and nares gave the highest detection rates as single sites. A combination of two 
swabs improved MRSA detection rates with the best combination being groin/throat (89.6%; 
62.5%–100%). A combination of three swab sites improved MRSA detection rate to 94.2% 
(81%–100%) with the best combination being groin/nose/throat. Certain combinations were 
associated with low detection rates. MRSA detection rates also varied with different culture 
methods.
Conclusion: A combination of three swabs from different body sites resulted in the highest 
detection rate for MRSA colonization. The use of three swab sites would likely improve the 
recognition and treatment of MRSA colonization, which may in turn reduce infection and 
transmission of MRSA to other patients.
Keywords: Staphylococcus colonization, swab sites, MRSA detection
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) has become a major cause of 
hospital-associated infection since it was first discovered in Britain in the 1960s soon 
after the beta-lactam methicillin was introduced for clinical use against Staphylococci.1 
The emergence of MRSA infection has had a negative impact on hospital costs, result-
ing in longer hospital stays as well as morbidity and mortality.2,3
MRSA colonization is a major risk factor for subsequent MRSA infection.4,5 
In the USA and Singapore, studies found that 8.5% and 15% of MRSA-colonized 
patients, respectively, developed MRSA infection over subsequent years.4,5 The pres-
ence of MRSA at multiple sites strongly predicts development of MRSA infection.6,7 
Colonized patients are an important reservoir of MRSA in hospitals, and diagnostic 
clinical samples can miss ∼35%–84% of these colonized patients.8,9
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There is no general consensus on effective control mea-
sures and the optimum anatomical swabbing sites, which 
are least costly, for use as an infection control measure for 
MRSA.9 Studies have been devised to determine the optimal 
site or combination of sites for detection of MRSA coloniza-
tion. Issues of detection method, cost, efficiency, accuracy, 
and study design have been considered. Different countries 
have different policies on the number of sites for screening 
of MRSA colonization for optimum results. In the USA, 
nasal swabbing as the single site is recommended while in 
the UK, at least two sites are recommended.9–11
Bacteremia surveillance has been used as a passive 
method for measuring effectiveness of MRSA control meth-
ods, but this has a disadvantage of requiring long follow-up 
to determine whether infection control interventions have had 
an effect in a hospital.12 There is a need to evaluate other sur-
veillance measures to achieve optimum control of MRSA.13 
Our study is aimed at establishing the significance of MRSA 
isolation from different sites suspected of colonization as a 
surveillance measure.
Methods
Selection of articles for inclusion
Candidate articles were selected for the reference docu-
ment, first on the basis of title, and then on reading the 
abstract. All candidate articles were retrieved before final 
selection. The articles qualified for selection for review if 
they met the following criteria: 1) original research writ-
ten in English and published in a peer-reviewed journal; 
2) explicit information on MRSA colonization sites; and 
3) any article published after 1966 providing data on cul-
ture isolates of MRSA at both nasal and extra-nasal and 
results were available.
Focus of the study
The focus of this study was, primarily, to analyze MRSA 
colonization sites or multiple MRSA colonization sites as a 
method of MRSA detection.
Literature search
The study was based on an updated literature search in 
Medline. The search terms were: “MRSA surveillance”, 
“Methicillin-resistant Staphylococcus aureus surveillance”, 
“MRSA”, “colonization site”, (“Screening” OR Swab OR 
surveillance AND MRSA). The database search was supple-
mented by a bibliographic search in previous reviews in the 
field. The authors read all the abstracts to retrieve relevant 
articles, minimizing the possibility of selective selection.
Data extraction
The data extracted from each of the included studies con-
sisted of the first author; year of publication; study design; 
country and period of the study; number of patients and/
or isolates of MRSA; and the type of the culture specimen 
for MRSA, the site of MRSA isolation, and the percentage 
sensitivity of the MRSA isolates at each site in relation to 
the total sites.
Results
We reviewed 3,211 abstracts and 177 manuscripts, and 160 
were excluded either due to the fact that the swabbing data 
were only from nasal sites or that the study population were 
mostly children. Seventeen full articles met the criteria for 
analysis as they had data on screening of both nasal and 
extra-nasal sites of adults at admission (Table 1).14–30 The 
studies included for analysis were conducted between 1996 
and 2014 (n=52,642 patients). Seven of the studies were 
conducted in South America, six in Europe, four in Asia, 
and none in Africa. Seven studies had study population from 
general wards, six from intensive care unit (ICU), and three 
from both ICU and general wards, while one was conducted 
on ward and outpatients. Eleven studies were prospectively 
while six were retrospectively done. Out of the 17 studies, 16 
of them used directly plated MRSA culture media and one 
used both directly plated MRSA culture media and broth-
enriched culture media. MRSA isolates were confirmed by 
disc diffusion assay in 16 studies, and in one study MRSA 
isolates were confirmed by both disc diffusion and molecular 
assays. Four studies had low MRSA prevalence of less than 
6% (1.3%–4.1%), while the prevalence of MRSA in nine 
studies were high at $6% (6%–25%), and four studies did 
not state the prevalence of MRSA.
Fifteen of the 17 studies had nasal MRSA detection of 
less than 90% as a single area of MRSA colonization and the 
MRSA detection ranged from 34% to 89.7%, and only two 
of the 15 studies had MRSA nasal sensitivity of $90% as a 
single area of MRSA colonization.24,25 The single-site screen-
ing of nares showed low MRSA in endemic areas15,19,25,27 due 
to a high proportion of MRSA detected by nasal screening of 
75.1% with a range of (65%–90%) (Table 2). Nasal coloniza-
tion showed MRSA detection sensitivity of less than 50% 
(34%–48%) in three studies.16,21,29
Seven studies showed less than 90% MRSA detection 
sensitivity when nasal MRSA colonization was combined 
with one extra-nasal site.14,16,19,20,23,29,30 Four studies had nasal/
throat; five studies nasal or throat/groin; three studies had 
nasal/rectum; and one study had nasal/skin or wound as 
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best two combinations for MRSA detection sensitivity. Four 
studies had nasal/throat/groin; three studies had nasal/throat/
rectum; while each of the two single studies had nasal/axilla/
rectum and nasal/wound/perineum, respectively, as three 
best combinations for MRSA detection sensitivity (Table 1). 
Detection of MRSA colonization was enhanced by using 
broth-enriched culture media and performing molecular 
assay, and this helped in rapid detection and identification 
of MRSA from mixed flora samples.20,22
Discussion
Colonized patients are important reservoir of MRSA in hospi-
tals, and diagnostic clinical samples can miss ∼35%–84% of 
these colonized patients.8,9 The level of endemicity of MRSA 
determines the kind of screening program needed in order 
not to miss occult carriers of MRSA and, therefore, increase 
cross transmission of MRSA hospital infection.19,25,26 The 
importance of doing the MRSA colonization screening has 
been marred with issues of cost-benefit analysis and the indi-
cation for it.19,22,27 Various countries have different policies 
on the number of sites for screening of MRSA colonization 
with optimum results.
Prevalence of MRSA colonization is not the same on dif-
ferent sites of patients’ body, such as the axilla, hairline, groin, 
nose, perineum, rectum, throat, skin breakdown areas, eyes, 
and vagina.14–30 The throat and nares show higher colonization 
detection as single sites ranging from 50.5% to 89.7%.14–20,22–28,30 
The two studies that showed $90% nasal MRSA colonization 
sensitivity as single site still needed extra-nasal combination 
to have required Negative Predictive Value of MRSA detec-
tion.24,25 Single-site screening such as the nasal cavity is optimal 
for endemic areas with low MRSA prevalence,15,19,25,27 and 
this single site is likely to miss significant detection of MRSA 
colonization in high-risk population.14–16,21,29 The nasal cavity 
as a single site for detection of MRSA colonization was not 
able to meet MRSA detection of $90% in 15 of the 17 studies 
under review.14–23,26–30 The study by El-Bouri14 found 50% of 
two swab combinations were better than single nasal swabbing 
and 25% were likely missed by using nasal swabbing alone. 
This was also found in studies by Mertz et al and Bignardi 
and Lowes.31–34
Combination swabs from two sites improved MRSA 
detection rate to 50% with best combination being that of 
nasal or throat/groin,18,22,24,28 followed by nasal/rectum or 
perineum.15,17,21
A three-site combination improved detection rate to 
99% with the best combination being that of nasal/throat/
groin or perineum or rectum.14,16,19,20,28,30 In another study, the 
three-site combination did not reach the $90% sensitivity,23 
though the overall MRSA colonization at any site was 12.2% 
(1.3%–24%), and this could be due to a variation in the 
MRSA detection method. Nasal colonization was 47.6% 
(22.2%–87%), nasal plus one extra-nasal combination was 
89.6% (62.5%–100%), and nasal plus two extra-nasal sites 
combination was 94.2% (81%–100%), as shown in Table 2. 
Similar findings were reported in a systematic review con-
ducted by McKinnell et al.31
Most of the studies under review for extra-nasal screen-
ing were done in developed countries of USA, Europe, 
and Asia even though many studies have indicated the 
prevalence of MRSA in countries of Africa. Apart from 
level of endemicity, cost-benefit analysis has been mainly 
put under consideration when it comes to either using nasal 
swabbing alone or combination of extra-nasal sites.15,32,35 
Another issue is to do with acceptability of the method of 
swabbing at certain sites, like throat and perineum, by the 
study population.15,27,36–39 Some studies found that throat 
swabbing was better at MRSA detection than nasal swab-
bing.14,16,27,36–39 Fifteen of the 17 studies (88%) reviewed 
favored inclusion of extra-nasal swabbing for the detection 
of MRSA colonization. Two studies under review showed 
that the method of MRSA detection has effect on the detec-
tion of MRSA at different sites.20,22 Lauderdale et al20 found 
that direct culture method missed ∼50% detection rate of 
MRSA from nasal swabbing as compared to broth-enriched 
medium. Broth-enriched culture improved detection rate 
of MRSA by 24% in swabs from the throat, axilla, and 
perineum. These results concurred with those of Grmek-
Kosnik et al and Nonhoff et al.40,41 The variation in the 
detection rate at different sites could also be attributed to 
MRSA load and method of detection and decolonization 
procedures.23,42 The association was not seen in the study by 
Baker et al,23 where it was found that the strongest predic-
tor of extra-nasal colonization was nasal colonization and 
not broth-enriched medium. Currie et al15 found that the 
sensitivity of rectal swabs increased from 59% to 67% for 
MRSA-Select plates when mannitol-salt agar (MSA-OX) 
with 4 mg/L oxacillin culture was used, but there was no 
significant change in sensitivities of nasal and open-skin-
site swabs with MSA-OX culture. Use of PCR methods 
did not show any significant difference in the detection of 
MRSA.23 The anatomical sites to be swabbed also have an 
effect on the culture results due to the fact that participants 
may decline to give consent, due to psycho-social stigma 
associated with very private or anatomically sensitive areas 
of the body to be swabbed. The throat or posterior pharynx, 
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Table 1 Participants, bacteriological testing, and outcomes of MRSA testing for identification of sites of MRSA colonization
Author name, 
country
Period of study Study  
design
MRSA detection method Swabbing method  
and site
Study population 
and size
MRSA positive 
number (%)
MRSA site colonization Best site combination
Nasal Extra-nasal Proportion to be  
missed if nasal alone
Two Three
El-Bouri and 
El-Bouri,14 Wales
January 2010– 
November 2012
Retrospective Chromogenic MRSA medium/ 
Columbia blood agar
Only simultaneously swabbed 
patients of all anatomical sites 
were accepted
Adults at high risk for  
MRSA due to frequent  
re-admission or  
others (4,769)
925/4,769 (19.4%) 467/925 (50.5%) 458/925 (49.5%) 365 (39.5%) Throat/groin 74.5%  
(71.7–77.3) 
Nose/groin 72.1%  
(69.2–75)
Throat/nose/groin 
92% (90.1–93.6) 
Nose/throat/perineum 
91% (88.9–92.7)
Currie et al,15  
Canada
January 2004– 
June 2007
Descriptive  
analysis
MSA-OX, 
MSA-FOX, 
MRSA-Select
First set of screening swabs All surgical and medical 
patient with HA-MRSA 
risk factors (23,365)
627/2,3365 (2.7%) 419/627 (66.8%) 208/627 (33.1%) 160 (34%) Nares/rectum 586/612  
(96% 94–98)
Jang et al,16  
Republic of Korea
March 2010– 
February 2011
Prospective  
observational
BBL™ CHROMagar™ MRSA 
medium
Swabbed at the time of  
admission, 48 hours after  
admission, and then weekly
Adult patients (282) 59/282 (21%) 20/59 (34%) 39/59 (66.1%) 66% Nasal/throat 50/59 
(84.7%)
Nasal/throat/rectum 
(94.9%)
Yang et al,17 USA February 2005– 
October 2007
Prospectively MSA-OX Swabbing once at anatomic  
sites in MRSA infected patients
Adults with SSTIs (117) 48/71 (67%) 23/71 (32.4%) 17/71 (24%) Nasal/inguinal (96%)
Datta et al,18 India January 2009– 
June 2010
Active  
surveillance
Blood agar and Mac Conkey  
agar and disc diffusion test  
using 30 ug cefoxitin disc on  
Mueller Hinton agar
Single anatomic swabbing Adults in ICU (400) 90/400 (22.5%) 70/90 (77.8%) 20/90 (22.2%) 11 (12.2%) Nose/throat 86/90 (95.5%), 
Throat/groin 84/90 (93.3%), 
Nose/groin 82/90 (91.1%)
Girou et al,19  
France
1993–1996 Prospective Chapman agar Swab from nasal, perineum,  
and axilla at admission and  
once a week
High-risk patients  
from MICU (3,686)
150/3,686 (4.1%) 35/45 (78.5%) 16/45 (35.6%) 5/45 (11%) Nasal/perineum (88.9%) Nasal/throat/perineum 
(98%)
Lauderdale et al,20  
Taiwan
August 2005– 
February 2006
Retrospective Sheep blood agar (SBA) and  
CHROM agar MRSA and  
broth-enriched culture
Swab sample set of nose,  
throat or sputum, axilla,  
and perineum within  
24 hours admission
Patients on admission  
to a medical and  
surgicaI ICU (650)
65/650 (10%) Direct  
culture (157/650  
[24%] broth- 
enriched)
114/157 (72.6%) 43/157 (27.3%) 27 (17.2%) Nasal/throat 134/157 (85.4%) Nasal/throat/perineum 
146/157 (93.2%)
Eveillard et al,21  
France
July 2002– 
June 2003
Prospective Mannitol salt agar  
(MSA-Ofloxacin)
Screen swab at different  
anatomic sites on  
admission and also clinical  
sample and TID calculated
1,250 from ICU and  
other wards
123/1,250 (9.8%) 53/123 (43.1%) 70/123 (56.9%) 54.3% Nose/rectum (91.9%) Nose/axilla/rectum 
(100%)
Hombach et al,22 
Switzerland
August 2007– 
August 2008
Prospective BD GeneOhm™ MRSA Assay,  
the Xpert™ MRSA assay  
and broth-enriched culture
Swabs from different sites on  
admission from MRSA  
high-risk patients
425 29/425 (6.8%) 26/29 (89.7%) 22/29 (76%) #1 Nose/groin (100%)
Baker et al,23 USA October 2008– 
February 2009
Prospective Chromogenic agar plate Swabs from acute care patients 
within 36 hours of admission
150 16/150 (10.7%) 9/16 (56.2%) 6/16 (37.5%) 3 (2%) Nasal/oropharynx (62.5%) Nasal/oropharynx/
perineum (81%)
Mermel et al,24 USA September 2007– 
March 2008
Retrospective MRSA-selective chromogenic  
medium and sheep blood agar
Adults inpatients previously 
identified as MRSA positive 
during the year prior to 
enrollment
53 Not stated 48/53 (91%) 40/53 (75.5%) Similar sensitivity but  
combined samples  
increasing negative  
predictive value
Nares/groin (98%)
Fishbain et al,25 USA August– 
November 2000
Prospective  
surveillance
5% sheep agar and MRSA  
screen agar
Adults on admission, swabs  
within 48 hours from both  
nares and both axilla
535 20/535 (3.7%) 18/20 (90%) 5/20 (25%) Similar sensitivity but  
combined samples  
increasing negative  
predictive value
Nasal/axillary (100%)
Lucet et al,26 France July 1997– 
December 1997
Prospective  
multicenter
Various media according  
to center
Adults in ICU swabs within  
24 hours admission from  nose 
and skin (both axilla and groin)
2,347 162/2,347 (6.9%) 126/162 (77.8%) 72/162 (44.4%) 19/162 (7.2%) Nasal/skin 148/162 (92%)
Papia et al,27 
Canada
May 1996– 
May 1997
Case control Mannitol agar Swabs from adults in acute  
care ward from different sites
1,742 23/1,742 (1.3%) 15/23 (65.2%) 13/23 (56.5%) 6/23 (26.1%) Nasal/wound (91.3%) Nasal/wound/
perineum (95.7%)
Lautenbach et al,28 
USA
January 2008– 
May 2008
Cross-section ChromAgar Swabs on admission by  
research nurse and self on  
admission from different  sites
56 Not stated 46/55 (84%) 48/55 (87%) 3/55 (5.5%) Nares/throat 50/55 (91%) Nares/throat/groin 
(98%)
Senn et al,29 USA 2006–2009 Retrospective M-Staphylococcus and  
MRSA-select agar
Swabs from different anatomic 
sites on admission for culture 
and PCR on adults
12,456 3,137/12,456 (25.2%) 1,509/3,137 (48%) 1,628/3,137 (51.9%) 1,320/3,137 (42.1%) Groin/throat (89%) Nose/groin/throat 
(96%)
Bitterman et al,30 
Israel
2003–2006 Retrospective BBL CHROMagar MRSA Swabs from sites from  
ICU and non-ICU patients  
from screening sample (SS) and 
clinical diagnostic sample (CDS)
Not stated 359 243/359 (67.7%) 117/359 (32.3%) 80/359 (22.2%) Nares/perineum (89.6%) Nares/perineum/
throat (93.6%)
Abbreviations: OX, Ofloxacin; FOX, cefoxitin; MRSA, methicillin-resistant Staphylococcus aureus; TID, theoretical isolation days; ICU, intensive care unit; HA, hospital 
associated; SSTI, skin and soft tissue infection; MICU, medical ICU; PCR, polymerase chain reaction.
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Table 1 Participants, bacteriological testing, and outcomes of MRSA testing for identification of sites of MRSA colonization
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MRSA detection method Swabbing method  
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Study population 
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MRSA positive 
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MRSA site colonization Best site combination
Nasal Extra-nasal Proportion to be  
missed if nasal alone
Two Three
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January 2010– 
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(84.7%)
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Active  
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Blood agar and Mac Conkey  
agar and disc diffusion test  
using 30 ug cefoxitin disc on  
Mueller Hinton agar
Single anatomic swabbing Adults in ICU (400) 90/400 (22.5%) 70/90 (77.8%) 20/90 (22.2%) 11 (12.2%) Nose/throat 86/90 (95.5%), 
Throat/groin 84/90 (93.3%), 
Nose/groin 82/90 (91.1%)
Girou et al,19  
France
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and axilla at admission and  
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High-risk patients  
from MICU (3,686)
150/3,686 (4.1%) 35/45 (78.5%) 16/45 (35.6%) 5/45 (11%) Nasal/perineum (88.9%) Nasal/throat/perineum 
(98%)
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broth-enriched culture
Swab sample set of nose,  
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24 hours admission
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to a medical and  
surgicaI ICU (650)
65/650 (10%) Direct  
culture (157/650  
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enriched)
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high-risk patients
425 29/425 (6.8%) 26/29 (89.7%) 22/29 (76%) #1 Nose/groin (100%)
Baker et al,23 USA October 2008– 
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Prospective Chromogenic agar plate Swabs from acute care patients 
within 36 hours of admission
150 16/150 (10.7%) 9/16 (56.2%) 6/16 (37.5%) 3 (2%) Nasal/oropharynx (62.5%) Nasal/oropharynx/
perineum (81%)
Mermel et al,24 USA September 2007– 
March 2008
Retrospective MRSA-selective chromogenic  
medium and sheep blood agar
Adults inpatients previously 
identified as MRSA positive 
during the year prior to 
enrollment
53 Not stated 48/53 (91%) 40/53 (75.5%) Similar sensitivity but  
combined samples  
increasing negative  
predictive value
Nares/groin (98%)
Fishbain et al,25 USA August– 
November 2000
Prospective  
surveillance
5% sheep agar and MRSA  
screen agar
Adults on admission, swabs  
within 48 hours from both  
nares and both axilla
535 20/535 (3.7%) 18/20 (90%) 5/20 (25%) Similar sensitivity but  
combined samples  
increasing negative  
predictive value
Nasal/axillary (100%)
Lucet et al,26 France July 1997– 
December 1997
Prospective  
multicenter
Various media according  
to center
Adults in ICU swabs within  
24 hours admission from  nose 
and skin (both axilla and groin)
2,347 162/2,347 (6.9%) 126/162 (77.8%) 72/162 (44.4%) 19/162 (7.2%) Nasal/skin 148/162 (92%)
Papia et al,27 
Canada
May 1996– 
May 1997
Case control Mannitol agar Swabs from adults in acute  
care ward from different sites
1,742 23/1,742 (1.3%) 15/23 (65.2%) 13/23 (56.5%) 6/23 (26.1%) Nasal/wound (91.3%) Nasal/wound/
perineum (95.7%)
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USA
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Cross-section ChromAgar Swabs on admission by  
research nurse and self on  
admission from different  sites
56 Not stated 46/55 (84%) 48/55 (87%) 3/55 (5.5%) Nares/throat 50/55 (91%) Nares/throat/groin 
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Senn et al,29 USA 2006–2009 Retrospective M-Staphylococcus and  
MRSA-select agar
Swabs from different anatomic 
sites on admission for culture 
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12,456 3,137/12,456 (25.2%) 1,509/3,137 (48%) 1,628/3,137 (51.9%) 1,320/3,137 (42.1%) Groin/throat (89%) Nose/groin/throat 
(96%)
Bitterman et al,30 
Israel
2003–2006 Retrospective BBL CHROMagar MRSA Swabs from sites from  
ICU and non-ICU patients  
from screening sample (SS) and 
clinical diagnostic sample (CDS)
Not stated 359 243/359 (67.7%) 117/359 (32.3%) 80/359 (22.2%) Nares/perineum (89.6%) Nares/perineum/
throat (93.6%)
Abbreviations: OX, Ofloxacin; FOX, cefoxitin; MRSA, methicillin-resistant Staphylococcus aureus; TID, theoretical isolation days; ICU, intensive care unit; HA, hospital 
associated; SSTI, skin and soft tissue infection; MICU, medical ICU; PCR, polymerase chain reaction.
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perineum, and rectum are likely to limit the sites available 
for access due to increased number of participants declining 
to give consent to swabbing, thus leading to discrepancy 
of results.22,23
Conclusion
We concur with previous published findings based on 
localized research analysis. Our systemic review of 
52,642 cases indicates that a combination of three swabs 
from different sites provided the highest detection rate of 
MRSA colonization. The use of three swab sites is likely to 
improve recognition and treatment of MRSA, which may in 
turn reduce infection and transmission to other patients in 
hospital despite associated incremental costs.
Recommendation
The prevalence of MRSA carriage plays an important role 
in strategies used to manage colonization. The decision on 
the optimal sampling sites for MRSA detection should be 
determined by the goal of the intervention. If the intention is 
eradication in low-prevalence, MRSA-colonized populations, 
prospective surveillance and infection control should be re-
enforced. For reduction in high-prevalence settings, prospective 
surveillance should be considered with universal screening.
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